In the 1960s, because of its professional and efficient organization, Schazoo entered into licensing
agreements with International Companies of repute like:
In the 1960s, because of its professional and efficient organization, Schazoo entered into licensing
agreements with International Companies of repute like:
1959-1975
1964-1971
1962-1971
1959-1971
1963-1971
1963-1972
1962-1971
1964-1989
Merck
UPJOHN (Merged with Pfizer)
NORDMARK
JANSSEN PHARMACEUTICAL
LEPETIT (Merged with Aventis)
DAGRA M.V
CHEMISCHE WERKE ALBERT
HEINRICH MACK (MERGED with Pfizer)
Germany
U.S.A.
Germany
Belgium
Italy
Holland
Germany
Germany
Today, Schazoo Zaka is one of the fastest growing national pharmaceutical company in Pakistan. The Company’s name is associated with reliability, honor and quality. It has been tested and approved over time by other Associated Companies, Doctors and Customers.
With a wide range of products covering the major therapeutic classes, having a purpose built manufacturing unit, cGMP practices, and major focus of Quality Assurance & Control, Schazoo Zaka continues to follow its vision of leading the way to a healthier world.
Schazoo Zaka is working in the following segments/therapeutic classes:
Schazoo Zaka will continue with its commitment of providing high quality healthcare products at affordable prices to the people of Pakistan, and also in the international market. The company remains committed to its vision of leading the way to a healthier world. Schazoo Zaka will continue to come up with more healthcare products according to international standards. We have several products to be launched down the road.
The company is moving into the international market aggressively and it has planned a strategy to leverage the global generics market. Our aim is to reach all the high burden tuberculosis countries and work with them as a partner to eradicate tuberculosis from their respective soil. The primary goal of WHO’s Global Drug Facility (GDF) is to ensure reliable access to affordable TB drugs of known quality for DOTS program. As we are already supplying Anti-TB products to DOTS program in Pakistan, we intend to broaden this horizon to other markets through GDF procurement program.
As sales force is the most effective tool for the promotion of products, hence the following capabilities will be targeted in the sales staff for a better future:
The strategy towards the markets of the future not only comprises of creating capacities and physical assets; it incorporates a strong movement by Schazoo Zaka towards entering into strategic alliances and enhancing resident intellectual capital and adding value. Schazoo Zaka will continue to provide a professional working environment. The company will remain an equal opportunity employer. The Management is dedicated to make further investments in improving company operations.
The company has already entered the Nutraceuticals/Herbal formulations segment and plans to launch more products in this area. In addition, Schazoo Zaka is also manufacturing formulations for Pediatric tuberculosis having a pharmacologically recommended therapy for the treatment of tuberculosis in children. These formulations will take care of the little patients suffering from tuberculosis in high burden countries.
Besides Anti-TB drugs, Schazoo Zaka has a wide variety of products including Cardiovascular, Antidiabetic , products for orthopedic and respiratory diseases. In line with the company objectives, we will acquire significant share of these therapeutic classes from the target market.